MorphoSys (MOR) Stock Price, News & Analysis

Company Overview

MorphoSys AG is a clinical‐stage biopharmaceutical company specializing in the discovery and development of therapeutic antibodies for the treatment of cancer, autoimmune and inflammatory diseases. The company employs a proprietary human antibody library technology platform (HuCAL®) to generate fully human monoclonal antibodies and bispecific antibody formats. MorphoSys focuses on advancing its own pipeline programs while forging strategic partnerships and licensing agreements with major pharmaceutical companies to co‐develop and commercialize novel antibody therapies.

The company’s lead programs include tafasitamab (Monjuvi®), an anti‐CD19 immunotherapy approved in the United States for certain types of relapsed or refractory diffuse large B‐cell lymphoma, and pelabresib, an investigational BET inhibitor being evaluated in collaboration with GlaxoSmithKline for the treatment of myelofibrosis. In addition to its oncology focus, MorphoSys is advancing antibody candidates in areas such as solid tumors and autoimmune conditions. The company’s R&D operations are supported by research facilities in Planegg‐Martinsried, Germany, complemented by commercial and clinical development teams based in Cambridge and Boston, Massachusetts.

Founded in 1992 and headquartered near Munich, MorphoSys has built a global presence through collaborations and licensing deals with industry partners, including Incyte, Novartis and Janssen Biotech. The company’s shares trade on the NASDAQ under the symbol MOR and on the Frankfurt Stock Exchange. Under the leadership of President and CEO Jean-Paul Kress, MorphoSys continues to leverage its antibody engineering expertise to expand its pipeline, drive clinical programs forward and explore new therapeutic areas.

Key Stats

• Today's Range: $18.96 to $18.96
• 50-Day Range: $18.96 to $18.96
• 52-Week Range: $4.18 to $19.50
• Volume: N/A
• Average Volume: 1.02 million shs
• Market Capitalization: $2.86 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MOR Stock Analysis - Frequently Asked Questions

How have MOR shares performed this year?

MorphoSys' stock was trading at $18.96 at the beginning of 2025. Since then, MOR stock has increased by 0.0% and is now trading at $18.96.

When did MorphoSys IPO?

MorphoSys (MOR) raised $200 million in an initial public offering on Thursday, April 19th 2018. The company issued 8,300,000 shares at $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

How do I buy shares of MorphoSys?

Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MorphoSys own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MorphoSys investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), e.l.f. Beauty (ELF), EMCOR Group (EME), Disc Medicine (IRON) and Builders FirstSource (BLDR).

Company Calendar

• Today: 9/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MOR
• CIK: 1340243
• Web: www.morphosys.com
• Phone: (498) 989-9270
• Fax: 49-89-8992-7222
• Employees: 730
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$205.35 million
• Net Margins: -226.79%
• Pretax Margin: -225.77%
• Return on Equity: -694.31%
• Return on Assets: -22.55%

Debt

• Debt-to-Equity Ratio: 4.98
• Current Ratio: 1.38
• Quick Ratio: 1.38

Sales & Book Value

• Annual Sales: $238.28 million
• Price / Sales: 11.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 54.17

Miscellaneous

• Outstanding Shares: 150,621,000
• Free Float: 150,546,000
• Market Cap: $2.86 billion
• Optionable: Not Optionable
• Beta: 1.20